Learn more
of what is worth knowing

Growing complexity of drug discovery pipelines has made one thing clear: platform technologies must become more adaptable. The conventional approach, tailoring a unique assay for each modality, is increasingly impractical. The time, material, and expertise required to adjust for each format slows discovery and limits comparability across programs.